Ischemic heart diseases: Current treatments and future

Journal of Controlled Release

Volumn 140, Issue 3, 2009, Pages 194-202

  Choi, Donghoon ^a   Hwang, Ki Chul ^a   Lee, Kuen Yong ^b   Kim, Yong Hee ^b  

^a Yonsei Cardiovascular Research Institute   (South Korea)

^b Hanyang University   (South Korea)

Author keywords

Cell and gene therapy; Ischemic heart disease; Percutaneous coronary intervention; Polymeric drug delivery system; Protein therapy

Indexed keywords

GENE THERAPY; ISCHEMIC HEART DISEASE; PERCUTANEOUS CORONARY INTERVENTION; POLYMERIC DRUG DELIVERY SYSTEM;

CARDIOLOGY; COMPETITION; DRUG DELIVERY; FUNCTIONAL POLYMERS; GENETIC ENGINEERING; OXYGEN SUPPLY; POLYMERS; SURGERY;

PROTEINS;

ALGINIC ACID; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; CHITOSAN; COPOLYMER; FIBRIN; FIBRINOGEN RECEPTOR ANTAGONIST; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; FONDAPARINUX; GELATIN; HEAT SHOCK PROTEIN 27; HEPARIN; HYALURONIC ACID; LOW MOLECULAR WEIGHT HEPARIN; MACROGOL; PLATELET DERIVED GROWTH FACTOR BB; POLYGLUTAMIC ACID; POLYMER; PROTEIN C JUN; PROTEIN DERIVATIVE; SMALL INTERFERING RNA; THIENOPYRIDINE DERIVATIVE; THROMBIN INHIBITOR; TRANSACTIVATOR PROTEIN; UNINDEXED DRUG; VASCULOTROPIN;

ACUTE CORONARY SYNDROME; ALLOGENEIC STEM CELL TRANSPLANTATION; ANGIOGENIC GENE THERAPY; ATHEROSCLEROSIS; CELL THERAPY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COLLATERAL CIRCULATION; CONTROLLED RELEASE FORMULATION; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; DRUG MECHANISM; HEART INFARCTION; HEART MUSCLE OXYGEN CONSUMPTION; HEART SURGERY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYDROGEL; ISCHEMIC HEART DISEASE; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RECURRENT DISEASE; RESTENOSIS; REVIEW; THROMBOEMBOLISM; THROMBOSIS; TRANSGENE; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; CORONARY ARTERY BYPASS; DRUG DELIVERY SYSTEMS; EXCIPIENTS; FIBRINOLYTIC AGENTS; GENE THERAPY; HUMANS; HYDROGELS; MYOCARDIAL ISCHEMIA; PROTEINS; TISSUE THERAPY;

EID: 70450278838     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2009.06.016     Document Type: Review

References (115)

1. Wang X.J., and Li Q.P. The roles of mesenchymal stem cells (MSCs) therapy in ischemic heart diseases. Biochem. Biophys. Res. Commun. 359 (2007) 189-193
2. Templin C., Kotlarz D., Faulhaber J., Schnabel S., Grote K., Salguero G., Luchtefeld M., Hiller K.H., Jakob P., Naim H.Y., Schieffer B., Hilfiker-Kleiner D., Landmesser U., Limbourg F.P., and Drexler H. Ex vivo expanded hematopoietic progenitor cells improve cardiac function after myocardial infarction: role of beta-catenin transduction and cell dose. J. Mol. Cell. Cardiol. 45 (2008) 394-403
3. Holmes Jr. D.R., Leon M.B., Moses J.W., Popma J.J., Cutlip D., Fitzgerald P.J., Brown C., Fischell T., Wong S.C., Midei M., Snead D., and Kuntz R.E. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 109 (2004) 634-640
4. Michaels A.D., and Chatterjee K. Angioplasty versus bypass surgery for coronary artery disease. Circulation 106 (2002) e187
5. Yang Y.M., and Moussa I. Percutaneous coronary intervention and drug-eluting stents. Can. Med. Assoc. J. 172 (2005) 323-325
6. Van Belle E., Abolmaali K., Bauters C., McFadden E.P., Lablanche J.M., and Bertrand M.E. Restenosis, late vessel occlusion and left ventricular function six months after balloon angioplasty in diabetic patients. J. Am. Coll. Cardiol. 34 (1999) 476-485
7. Bhatheja R., and Mukherjee D. Acute coronary syndromes: unstable angina/non-ST elevation myocardial infarction. Crit. Care Clin. 23 (2007) 709-735
8. Hirsh J. Low-molecular-weight heparin: a review of the results of recent studies of the treatment of venous thromboembolism and unstable angina. Circulation 98 (1998) 1575-1582
9. Anderson J.L., Adams C.D., Antman E.M., Bridges C.R., Califf R.M., Casey D.E., Chavey W.E., Fesmire F.M., Hochman J.S., Levin T.N., Lincoff A.M., Peterson E.D., Theroux P., Wenger N.K., Wright R.S., Smith S.C., Jacobs A.K., Adams C.D., Anderson J.L., Antman E.M., Halperin J.L., Hunt S.A., Krumholz H.M., Kushner F.G., Lytle B.W., Nishimura R., Ornato J.P., Page R.L., and Riegel B. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction-executive summary. J. Am. Coll. Cardiol. 50 (2007) 652-726
10. Sõti C., Nagy E., Giricz Z., Vígh L., Csermely P., and Ferdinandy P. Heat shock proteins as emerging therapeutic targets. Br. J. Pharmacol. 146 (2005) 769-780
11. Ferdinandy P., Szilvassy Z., and Baxter G.F. Adaptation to myocardial stress in disease states: is preconditioning a healthy heart phenomenon. Trends Pharmacol. Sci. 19 (1998) 223-229
12. Ferdinandy P. Myocardial ischaemia/reperfusion injury and preconditioning: effects of hypercholesterolaemia/hyperlipidaemia. Br. J. Pharmacol. 138 (2003) 283-285
13. Kwon J.H., Kim J.B., Lee K.H., Kang S.M., Chung N., Jang Y., and Chung J.H. Protective effect of heat shock protein 27 using protein transduction domain-mediated delivery on ischemia/reperfusion heart injury. Biochem. Biophys. Res. Commun. 363 (2007) 399-404
14. Pugh C.W., and Ratcliffe P.J. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat. Med. 9 (2003) 677-684
15. Javerzat S., Auguste P., and Bikfalvi A. The role of fibroblast growth factors in vascular development. Trends Mol. Med. 8 (2002) 483-489
16. Losordo D.W., and Dimmeler S. Therapeutic angiogenesis and vasculogenesis for ischemic diseasE: Part I: angiogenic cytokines. Circulation 109 (2004) 2487-2491
17. Banai S., Jaklitsch M.T., Casscells W., Shou M., Shrivastav S., Correa R., Epstein S.E., and Unger E.F. Effects of acidic fibroblast growth factor on normal and ischemic myocardium. Circ. Res. 69 (1991) 76-85
18. Schumacher B., Pecher P., von Specht B.U., and Stegmann T. Induction of neoangiogenesis in ischemic myocardium by human growth factors. First clinical results of a new treatment of coronary heart disease. Circulation 97 (1998) 645-650
19. Joseph-Silverstein J., and Rifkin D.B. Endothelial cell growth factors and the vessel wall. Semin. Thromb. Hemost. 13 (1987) 504-513
20. Hampton T.G., Amende I., Fong J., Laubach V.E., Li J., Metais C., and Simons M. Basic FGF reduces stunning via a NOS2-dependent pathway in coronary-perfused mouse hearts. Am. J. Physiol, Heart Circ. Physiol. 279 (2000) H260-H268
21. Buehler A., Martire A., Strohm C., Wolfram S., Fernandez B., Palmen M., Wehrens X.H., Doevendans P.A., Franz W.M., Schaper W., and Zimmermann R. Angiogenesis-independent cardioprotection in FGF-1 transgenic mice. Cardiovasc. Res. 55 (2002) 768-777
22. Stegmann T.J. FGF-1: a human growth factor in the induction of neoangiogenesis. Exp. Opin. Invest. Drugs 7 (1998) 2011-2015
23. Unger E.F., Banai S., Shou M., Lazarous D.F., Jaklitsch M.T., Scheinowitz M., Correa R., Klingbeil C., and Epstein S.E. Basic fibroblast growth factor enhances myocardial collateral flow in a canine model. Am. J. Physiol. 266 (1994) H1588-H1595
24. Udelson J.E., Dilsizian V., Laham R.J., Chronos N., Vansant J., Blais M., Galt J.R., Pike M., Yoshizawa C., and Simons M. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe chronic coronary artery disease. Circulation 102 (2000) 1605-1610
25. Claffey K.P., Abrams K., Shih S.C., Brown L.F., Mullen A., and Keough M. Fibroblast growth factor 2 activation of stromal cell vascular endothelial growth factor expression and angiogenesis. Lab. Invest. 81 (2001) 61-75
26. Seghezzi G., Patel S., Ren C.J., Gualandris A., Pintucci G., Robbins E.S., Shapiro R.L., Galloway A.C., Rifkin D.B., and Mignatti P. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J. Cell Biol. 141 (1998) 1659-1673
27. Tomanek R.J., Holifield J.S., Reiter R.S., Sandra A., and Lin J.J. Role of VEGF family members and receptors in coronary vessel formation. Dev. Dyn. 225 (2002) 233-240
28. Carmeliet P. Angiogenesis in health and disease. Nat. Med. 9 (2003) 653-660
29. Zachary I., and Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc. Res. 49 (2001) 568-581
30. Harada K., Friedman M., Lopez J.J., Wang S.Y., Li J., Prasad P.V., Pearlman J.D., Edelman E.R., Sellke F.W., and Simons M. Vascular endothelial growth factor administration in chronic myocardial ischemia. Am. J. Physiol. 270 (1996) H1791-H1802
31. Lopez J.J., Laham R.J., Stamler A., Pearlman J.D., Bunting S., Kaplan A., Carrozza J.P., Sellke F.W., and Simons M. VEGF administration in chronic myocardial ischemia in pigs. Cardiovasc. Res. 40 (1998) 272-281
32. Ruel M., and Sellke F.W. Angiogenic protein therapy. Semin. Thorac. Cardiovasc. Surg. 15 (2003) 222-235
33. Banai S., Jaklitsch M.T., Shou M., Lazarous D.F., Scheinowitz M., Biro S., Epstein S.E., and Unger E.F. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation 89 (1994) 2183-2189
34. Lazarous D.F., Shou M., Scheinowitz M., Hodge E., Thirumurti V., Kitsiou A.N., Stiber J.A., Lobo A.D., Hunsberger S., Guetta E., Epstein S.E., and Unger E.F. Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury. Circulation 94 (1996) 1074-1082
35. Toyota E., Matsunaga T., and Chilian W.M. Myocardial angiogenesis. Mol. Cell. Biochem. 264 (2004) 35-44
36. Simons M., Annex B.H., Laham R.J., Kleiman N., Henry T., Dauerman H., Udelson J.E., Gervino E.V., Pike M., Whitehouse M.J., Moon T., and Chronos N.A. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 105 (2002) 788-793
37. Asoh S., and Ohta S. PTD-mediated delivery of anti-cell death proteins/peptides and therapeutic enzymes. Adv. Drug Deliv. Rev. 60 (2008) 499-516
38. Nagai S., Asoh S., Kobayashi Y., Shidara Y., Mori T., Suzuki M., Moriyama Y., and Ohta S. Protection of hepatic cells from apoptosis induced by ischemia/reperfusion injury by protein therapeutics. Hepatol. Res. 37 (2007) 133-142
39. Arakawa M., Yasutake M., Miyamoto M., Takano T., Asoh S., and Ohta S. Transduction of anti-cell death protein FNK protects isolated rat hearts from myocardial infarction induced by ischemia/reperfusion. Life Sci. 80 (2007) 2076-2084
40. Shimizu S., Konishi A., Kodama T., and Tsujimoto Y. BH4 domain of antiapoptotic Bcl-2 family members closes voltage-dependent anion channel and inhibits apoptotic mitochondrial changes and cell death. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 3100-3105
41. Sugioka R., Shimizu S., Funatsu T., Tamagawa H., Sawa Y., Kawakami T., and Tsujimoto Y. BH4-domain peptide from Bcl-xL exerts anti-apoptotic activity in vivo. Oncogene 22 (2003) 8432-8440
42. Ono M., Sawa Y., Ryugo M., Alechine A.N., Shimizu S., Sugioka R., Tsujimoto Y., and Matsuda H. BH4 peptide derivative from Bcl-xL attenuates ischemia/reperfusion injury thorough anti-apoptotic mechanism in rat hearts. Eur. J. Cardio-Thorac. Surg. 27 (2005) 117-121
43. Milano G., Morel S., Bonny C., Samaja M., von Segesser L.K., Nicod P., and Vassalli G. A peptide inhibitor of c-Jun NH2-terminal kinase reduces myocardial ischemia-reperfusion injury and infarct size in vivo. Am. J. Physiol., Heart Circ. Physiol. 292 (2007) H1828-H1835
44. Hendel R.C., Henry T.D., Rocha-Singh K., Isner J.M., Kereiakes D.J., Giordano F.J., Simons M., and Bonow R.O. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect. Circulation 101 (2000) 118-121
45. Henry T.D., and Abraham J.A. Review of preclinical and clinical results with vascular endothelial growth factors for therapeutic angiogenesis. Curr. Interv. Cardiol. Rep. 2 (2000) 228-241
46. Henry T.D., Rocha-Singh K., Isner J.M., Kereiakes D.J., Giordano F.J., Simons M., Losordo D.W., Hendel R.C., Bonow R.O., Eppler S.M., Zioncheck T.F., Holmgren E.B., and McCluskey E.R. Intracoronary administration of recombinant human vascular endothelial growth factor (rhVEGF) to patients with coronary artery disease. Am. Heart J. 142 (2001) 872-880
47. Henry T.D., Annex B.H., McKendall G.R., Azrin M.A., Lopez J.J., Giordano F.J., Shah P.K., Willerson J.T., Benza R.L., Berman D.S., Gibson C.M., Bajamonde A., Rundle A.C., Fine J., and McCluskey E.R. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 107 (2003) 1359-1365
48. Laham R.J., Chronos N.A., Pike M., Leimbach M.E., Udelson J.E., Pearlman J.D., Pettigrew R.I., Whitehouse M.J., Yoshizawa C., and Simons M. Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a phase 1 open-label dose escalation study. J. Am. Coll. Cardiol. 36 (2000) 2132-2139
49. Beeres S.L., Atsma D.E., van Ramshorst J., Schalij M.J., and Bax J.J. Cell therapy for ischaemic heart disease. Heart 94 (2008) 1214-1226
50. Orlic D., Kajstura J., Chimenti S., Jakoniuk I., Anderson S.M., Li B., Pickel J., McKay R., Nadal-Ginard B., Bodine D.M., Leri A., and Anversa P. Bone marrow cells regenerate infarcted myocardium. Nature 410 (2001) 701-705
51. Kocher A.A., Schuster M.D., Szabolcs M.J., Takuma S., Burkhoff D., Wang J., Homma S., Edwards N.M., and Itescu S. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat. Med. 7 (2001) 430-436
52. Shi R.Z., and Li Q.P. Improving outcome of transplanted mesenchymal stem cells for ischemic heart disease. Biochem. Biophys. Res. Commun. 376 (2008) 247-250
53. Jackson J.D., Zhou G., Kuszynski C.A., Cai J., and Fox J.J. Induction of chimerism in mice using human MHC class I-mismatched Hoechst 33342 side population donor stem cells. Cell Transplant 11 (2002) 779-785
54. Mouquet F., Pfister O., Jain M., Oikonomopoulos A., Ngoy S., Summer R., Fine A., and Liao R. Restoration of cardiac progenitor cells after myocardial infarction by self-proliferation and selective homing of bone marrow-derived stem cells. Circ. Res. 97 (2005) 1080-1082
55. Planat-Benard V., Silvestre J.S., Cousin B., André M., Nibbelink M., Tamarat R., Clergue M., Manneville C., Saillan-Barreau C., Duriez M., Tedgui A., Levy B., Pénicaud L., and Casteilla L. Plasticity of human adipose lineage cells toward endothelial cells: physiological and therapeutic perspectives. Circulation 109 (2004) 656-663 Electronic publication 2004 Jan 20
56. Moelker A.D., Baks T., Wever K.M., Spitskovsky D., Wielopolski P.A., van Beusekom H.M., van Geuns R.J., Wnendt S., Duncker D.J., and van der Giessen W.J. Intracoronary delivery of umbilical cord blood derived unrestricted somatic stem cells is not suitable to improve LV function after myocardial infarction in swine. J. Mol. Cell. Cardiol. 42 (2007) 735-745
57. Kehat I., Kenyagin-Karsenti D., Snir M., Segev H., Amit M., Gepstein A., Livne E., Binah O., Itskovitz-Eldor J., and Gepstein L. Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. J. Clin. Invest. 108 (2001) 363-364
58. Min J.Y., Yang Y., Sullivan M.F., Ke Q., Converso K.L., Chen Y., Morgan J.P., and Xiao Y.F. Long-term improvement of cardiac function in rats after infarction by transplantation of embryonic stem cells. J. Thorac. Cardiovasc. Surg. 125 (2003) 361-369
59. Mack C.A., Patel S.R., Schwarz E.A., Zanzonico P., Hahn R.T., Ilercil A., Devereux R.B., Goldsmith S.J., Christian T.F., Sanborn T.A., Kovesdi I., Hackett N., Isom O.W., Crystal R.G., and Rosengart T.K. Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. J. Thorac. Cardiovasc. Surg. 115 (1998) 168-176
60. Giordano F.J., Ping P., McKirnan M.D., Nozaki S., DeMaria A.N., Dillmann W.H., Mathieu-Costello O., and Hammond H.K. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat. Med. 2 (1996) 534-539
61. Losordo D.W., Vale P.R., Hendel R.C., Milliken C.E., Fortuin F.D., Cummings N., Schatz R.A., Asahara T., Isner J.M., and Kuntz R.E. Phase 1/2 placebocontrolled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 105 (2002) 2012-2018
62. Vale P.R., Losordo D.W., Milliken C.E., Maysky M., Esakof D.D., Symes J.F., and Isner J.M. Left ventricular electromechanical mapping to assess efficacy of phVEGF(165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia. Circulation 102 (2000) 965-974
63. Symes J.s.F., Losordo D.W., Vale P.R., Lathi K.G., Esakof D.D., Mayskiy M., and Isner J.M. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann. Thorac. Surg. 68 (1999) 830-836
64. Rosengart T.K., Lee L.Y., Patel S.R., Sanborn T.A., Parikh M., Bergman G.W., Hachamovitch R., Szulc M., Kligfield P.D., Okin P.M., Hahn R.T., Devereux R.B., Post M.R., Hackett N.R., Foster T., Grasso T.M., Lesser M.L., Isom O.W., and Crystal R.G. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinical significant severe coronary artery disease. Circulation 100 (1999) 468-474
65. Laham R.J., Sellke F.W., Edelman E.R., Pearlman J.D., Ware J.A., Brown D.L., Gold J.P., and Simons M. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial. Circulation 100 (1999) 1865-1871
66. Grines C.L., Watkins M.W., Helmer G., Penny W., Brinker J., Marmur J.D., West A., Rade J.J., Marrott P., Hammond H.K., and Engler R.L. Angiogenic gene therapy (AGENT) trial in patients with stable angina pectoris. Circulation 105 (2002) 1291-1297
67. Manning M.C., Patel K., and Borchardt T. Stability of protein pharmaceuticals. Pharm. Res. 6 (1989) 903-918
68. Prokop A., Kozlov E., Carlesso G., and Davidson J.M. Hydrogel-based colloidal polymeric system for protein and drug delivery: physical and chemical characterization, permeability control and applications. Adv. Polym. Sci. 160 (2002) 119-173
69. Lee K.Y., and Yuk S.H. Polymeric protein delivery systems. Prog. Polym. Sci. 32 (2007) 669-697
70. Lee K.Y., and Mooney D.J. Hydrogels for tissue engineering. Chem. Rev. 101 (2001) 1869-1879
71. Sakiyama-Elbert S.E., and Hubbell J.A. Functional biomaterials: design of novel biomaterials. Ann. Rev. Mater. Res. 31 (2001) 183-201
72. Rault I., Frei V., Herbage D., Abdul-Malak N., and Huc A. Evaluation of different chemical methods for cross-linking collagen gel, films and sponges. J. Mater. Sci., Mater. Med. 7 (1996) 215-221
73. Inoue N., Bessho M., Furuta M., Kojima T., Okuda S., and Hara M. A novel collagen hydrogel cross-linked by γ -ray irradiation in acidic pH conditions. J. Biomater. Sci., Polym. Ed. 17 (2006) 837-858
74. Tabata Y., Miyao M., Ozeki M., and Ikada Y. Controlled release of vascular endothelial growth factor by use of collagen hydrogels. J. Biomater. Sci., Polym. Ed. 11 (2000) 915-930
75. Leu A., and Leach J.K. Proangiogenic potential of a collagen/bioactive glass substrate. Pharm. Res. 25 (2008) 1222-1229
76. Young S., Wong M., Tabata Y., and Mikos A.G. Gelatin as a delivery vehicle for the controlled release of bioactive molecules. J. Control. Release 109 (2005) 256-274
77. Sakakibara Y., Tambara K., Sakaguchi G., Lu F., Yamamoto M., Nishimura K., Tabata Y., and Komeda M. Toward surgical angiogenesis using slow-released basic fibroblast growth factor. Eur. J. Cardio-Thorac. Surg. 24 (2003) 105-111
78. Hosaka A., Koyama H., Kushibiki T., Tabata Y., Nishiyama N., Miyata T., Shigematsu H., Takato T., and Nagawa H. Gelatin hydrogel microspheres enable pinpoint delivery of basic fibroblast growth factor for the development of functional collateral vessels. Circulation 110 (2004) 3322-3328
79. Laurens N., Koolwijk P., and De Maat M.P.M. Fibrin structure and wound healing. J. Thromb. Haemost. 4 (2006) 932-939
80. Gwak S.J., Kim S.S., Sung K., Han J.H., Choi C.Y., and Kim B.S. Synergistic effect of keratinocyte transplantation and epidermal growth factor delivery on epidermal regeneration. Cell Transplant 14 (2005) 809-817
81. Jeon O., Ryu S.H., Chung J.H., and Kim B.S. Control of basic fibroblast growth factor release from fibrin gel with heparin and concentrations of fibrinogen and thrombin. J. Control. Release 105 (2005) 249-259
82. Afify A.M., Stern M., Guntenhoner M., and Stern R. Purification and characterization of human serum hyaluronidase. Arch. Biochem. Biophys. 305 (1993) 434-441
83. Shu X.Z., Liu Y.C., Luo Y., Roberts M.C., and Prestwich G.D. Disulfide cross-linked hyaluronan hydrogels. Biomacromolecules 3 (2002) 1304-1311
84. Leach J.B., and Schmidt C.E. Characterization of protein release from photo-cross-linkable hyaluronic acid-polyethylene glycol hydrogel tissue engineering scaffolds. Biomaterials 26 (2005) 125-135
85. Peattie R.A., Rieke E.R., Hewett E.M., Fisher R.J., Shu X.Z., and Prestwich G.D. Dual growth factor-induced angiogenesis in vivo using hyaluronan hydrogel implants. Biomaterials 27 (2006) 1868-1875
86. Cai S.S., Liu Y.C., Shu X.Z., and Prestwich G.D. Injectable glycosaminoglycan hydrogels for controlled release of human basic fibroblast growth factor. Biomaterials 26 (2005) 6054-6067
87. George M., and Abraham T.E. Polyionic hydrocolloids for the intestinal delivery of protein drugs: alginate and chitosan - a review. J. Control. Release 114 (2006) 1-14
88. Gombotz W.R., and Wee S.F. Protein release from alginate matrices. Adv. Drug Deliv. Rev. 31 (1998) 267-285
89. Augst A.D., Kong H.J., and Mooney D.J. Alginate hydrogels as biomaterials. Macromol. Biosci. 6 (2006) 623-633
90. Lee K.Y., Peters M.C., and Mooney D.J. Comparison of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in SCID mice. J. Control. Release 87 (2003) 49-56
91. Hao X.J., Silva E.A., Mansson-Broberg A., Grinnemo K.H., Siddiqui A.J., Dellgren G., Wardell E., Brodin L.A., Mooney D.J., and Sylven C. Angiogenic effects of sequential release of VEGF-A(165) and PDGF-BB with alginate hydrogels after myocardial infarction. Cardiovasc. Res. 75 (2007) 178-185
92. Rinaudo M. Chitin and chitosan: properties and applications. Prog. Polym. Sci. 31 (2006) 603-632
93. Lin Y.H., Liang H.F., Chung C.K., Chen M.C., and Sung H.W. Physically cross-linked alginate/N,O-carboxymethyl chitosan hydrogels with calcium for oral delivery of protein drugs. Biomaterials 26 (2005) 2105-2113
94. Mi F.L., Kuan C.Y., Shyu S.S., Lee S.T., and F Chang S. The study of gelation kinetics and chain-relaxation properties of glutaraldehyde-cross-linked chitosan gel and their effects on microspheres preparation and drug release. Carbohydr. Polym. 41 (2000) 389-396
95. Fujita M., Ishihara M., Morimoto Y., Simizu M., Saito Y., Yura H., Matsui T., Takase B., Hattori H., Kanatani Y., Kikuchi M., and Maehara T. Efficacy of photo-cross-linkable chitosan hydrogel containing fibroblast growth factor-2 in a rabbit model of chronic myocardial infarction. J. Surg. Res. 126 (2005) 27-33
96. Wu J., Su Z.G., and Ma G.H. A thermo- and pH-sensitive hydrogel composed of quaternized chitosan/glycerophosphate. Int. J. Pharm. 315 (2006) 1-11
97. Andreopoulos F.M., Deible C.R., Stauffer M.T., Weber S.G., Wagner W.R., Beckman E.J., and Russell A.J. Photoscissable hydrogel synthesis via rapid photopolymerization of novel PEG-based polymers in the absence of photoinitiators. J. Am. Chem. Soc. 118 (1996) 6235-6240
98. Zhao X., and Harris J.M. Novel degradable poly(ethylene glycol) hydrogels for controlled release of protein. J. Pharm. Sci. 87 (1998) 1450-1458
99. Zhang L., Furst E.M., and Kiick K.L. Manipulation of hydrogel assembly and growth factor delivery via the use of peptide-polysaccharide interactions. J. Control. Release 114 (2006) 130-142
100. Sperinde J.J., and Griffith L.G. Synthesis and characterization of enzymatically cross-linked poly(ethylene glycol) hydrogels. Macromolecules 30 (1997) 5255-5264
101. Yamaguchi N., and Kiick K.L. Polysaccharide-poly(ethylene glycol) star copolymer as a scaffold for the production of bioactive hydrogels. Biomacromolecules 6 (2005) 1921-1930
102. Andreopoulos F.M., and Persaud I. Delivery of basic fibroblast growth factor (bFGF) from photoresponsive hydrogel scaffolds. Biomaterials 27 (2006) 2468-2476
103. Gombotz W.R., and Pettit D.K. Biodegradable polymers for protein and peptide drug delivery. Bioconjugate Chem. 6 (1995) 332-351
104. Wang B., Zhu W., Zhang Y., Yang Z.G., and Ding J.D. Synthesis of a chemically cross-linked thermo-sensitive hydrogel film and in situ encapsulation of model protein drugs. React. Funct. Polym. 66 (2006) 509-518
105. Molina I., Li S.M., Martinez M.B., and Vert M. Protein release from physically cross-linked hydrogels of the PLA/PEO/PLA triblock copolymer-type. Biomaterials 22 (2001) 363-369
106. Jeong B., Bae Y.H., Lee D.S., and Kim S.W. Biodegradable block copolymers as injectable drug-delivery systems. Nature 388 (1997) 860-862
107. Obaidat A.A., and Park K. Characterization of glucose dependent gel-sol phase transition of the polymeric glucose-concanavalin A hydrogel system. Pharm. Res. 13 (1996) 989-995
108. Nagahara S., and Matsuda T. Hydrogel formation via hybridization of oligonucleotides derivatized in water-soluble vinyl polymers. Polym. Gels Networks 4 (1996) 111-127
109. Wang C., Stewart R.J., and Kopecek J. Hybrid hydrogels assembled from synthetic polymers and coiled-coil protein domains. Nature 397 (1999) 417-420
110. Stile R.A., Burghardt W.R., and Healy K.E. Synthesis and characterization of injectable poly(N-isopropylacrylamide)-based hydrogels that support tissue formation in vitro. Macromolecules 32 (1999) 7370-7379
111. Kavanagh C.A., Gorelova T.A., Selezneva I.I., Rochev Y.A., Dawson K.A., Gallagher W.M., Gorelov A.V., and Keenan A.K. Poly(N-isopropy acrylamide) copolymer films as vehicles for the sustained delivery of proteins to vascular endothelial cells. J. Biomed. Mater. Res. Part A 72A (2005) 25-35
112. Jiang H.L., and Zhu K.J. Comparison of poly(aspartic acid) hydrogel and poly(aspartic acid)/gelatin complex for entrapment and pH-sensitive release of protein drugs. J. Appl. Polym. Sci. 99 (2006) 2320-2329
113. Matsusaki M., and Akashi M. Novel functional biodegradable polymer IV: pH-sensitive controlled release of fibroblast growth factor-2 from a poly(γ-glutamic acid)-sulfonate matrix for tissue engineering. Biomacromolecules 6 (2005) 3351-3356
114. Layman H., Spiga M.G., Brooks T., Pham S., Webster K.A., Andreopoulos F.M., and Fotios M. The effect of the controlled release of basic fibroblast growth factor from ionic gelatin-based hydrogels on angiogenesis in a murine critical limb ischemic model. Biomaterials 28 (2007) 2646-2654
115. Peppas N.A., and Kim B. Stimuli-sensitive protein delivery systems. J. Drug Deliv. Sci. Technol. 16 (2006) 11-18